SCHEMBL5648741

SCHEMBL5648741

O=C(NCc1cccnc1)c1ccc(-c2nc3cc(F)c(Cl)cc3[nH]2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.43
LMNA P02545 5/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPK1 P28482 2/20 0.42
BLM P54132 1/20 0.42
HPGD P15428 5/20 0.42
PKM P14618 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NAMPT P43490 1/20 0.41
TSHR P16473 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HTT P42858 3/20 0.40
MMP13 P45452 1/20 0.40
POLB P06746 1/20 0.40
DYRK1A Q13627 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648735 0.96 NPSR1 (0.43) NPSR1LMNAALDH1A1MAPK1BLM
SCHEMBL5651274 0.82 SORT1 (0.52) NPSR1LMNAALDH1A1NAMPTSMN1; SMN2
SCHEMBL5651267 0.82 SORT1 (0.52) NPSR1LMNAALDH1A1NAMPTSMN1; SMN2
SCHEMBL5648386 0.80 FLT3 (0.44) KDM4E
SCHEMBL5653471 0.79 HTT (0.47) NPSR1LMNAALDH1A1MAPK1HPGD
SCHEMBL5648383 0.76 FLT3 (0.44) KDM4E
SCHEMBL5653421 0.75 TSHR (0.44) NPSR1LMNAALDH1A1MAPK1BLM
SCHEMBL5653423 0.75 TSHR (0.44) NPSR1LMNAALDH1A1MAPK1BLM
SCHEMBL5651264 0.73 L3MBTL1 (0.51) LMNAALDH1A1MAPK1HPGDCYP3A4
SCHEMBL4919514 0.71 ESRRG (0.58) NPSR1HPGDTSHRSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 NPSR1 27/4885LMNA 4376/4885ALDH1A1 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.